The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictor of response to neoadjuvant chemotherapy (NACT) in primary breast cancer.
A. S. Wenners
No relevant relationships to disclose
K. Mehta
No relevant relationships to disclose
S. Loibl
No relevant relationships to disclose
H. Park
No relevant relationships to disclose
N. Arnold
No relevant relationships to disclose
S. Hamann
No relevant relationships to disclose
J. Weimer
No relevant relationships to disclose
B. Ataseven
No relevant relationships to disclose
C. Schem
No relevant relationships to disclose
F. Khandan
No relevant relationships to disclose
C. Thomssen
No relevant relationships to disclose
W. Jonat
No relevant relationships to disclose
H. Holzhausen
No relevant relationships to disclose
G. Von Minckwitz
No relevant relationships to disclose
C. Denkert
No relevant relationships to disclose
M. Bauer
No relevant relationships to disclose